Daiichi Sankyo scouting for new biotech buyouts, partnerships

With late-stage data on an experimental blood thinner with blockbuster potential due next year and ambitious plans to push revenue, Daiichi Sankyo's European chief tells Bloomberg that the Japanese pharma company would like to do some more deals along the lines of its $235 million buyout of Germany's U3 Pharma AG. Reinhard Bauer made it clear that he's not on the lookout for any generic drugs or meds already approved for use. U3, which Daiichi Sankyo bought two years ago, provided the...